Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial

医学 催眠药 彭布罗利珠单抗 肿瘤科 临床终点 内科学 临床研究阶段 头颈部鳞状细胞癌 实体瘤疗效评价标准 头颈部癌 临床试验 癌症 免疫疗法
作者
Douglas Adkins,Jessica C. Ley,Jingxia Liu,Peter Oppelt
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (7): 888-900 被引量:16
标识
DOI:10.1016/s1470-2045(24)00204-3
摘要

Background VEGF, a key mediator of angiogenesis and resistance to immunotherapy, is overexpressed in head and neck squamous cell carcinoma (HNSCC). We aimed to determine the recommended phase 2 dose of ramucirumab, a selective VEGFR2 inhibitor, given with pembrolizumab and the objective response rate of this combination as first-line treatment for recurrent or metastatic HNSCC. Methods In this single-centre, phase 1/2 trial, which was done at Washington University (St Louis, MO, USA), eligible patients were aged 18 years or older with incurable recurrent or metastatic HNSCC and an Eastern Cooperative Oncology Group performance status of 0–2. Patients in phase 2 were required to have had no previous systemic therapy for recurrent or metastatic disease. In a dose de-escalation phase 1 design, patients received ramucirumab (starting dose 10 mg/kg given intravenously) and pembrolizumab (200 mg intravenously) on day 1 of each 21-day cycle. The recommended phase 2 dose of ramucirumab was defined as the highest dose at which one or fewer of three patients had dose-limiting toxicity during cycle one (primary endpoint of phase 1). In a Simon's two-stage phase 2 design, patients received the recommended phase 2 dose of ramucirumab and pembrolizumab. Tumour response (primary endpoint of phase 2) was assessed by Response Evaluation Criteria in Solid Tumours (version 1.1). We hypothesised that there would be an objective response rate of 32% or higher (null ≤13%). Eight or more responses among 33 evaluable patients (those with at least one response assessment) was evidence for activity (80% power; one-sided α=0·05). Analyses were done per protocol. The trial is registered with ClinicalTrials.gov, NCT03650764, and is closed to enrolment. Findings Between June 18, 2019, and Feb 11, 2021, three patients enrolled and were treated in phase 1 and 37 patients in phase 2. Median age of all patients was 64 years (IQR 59–72). 36 (90%) of 40 patients were men and four (10%) were women, and 36 (90%) patients were White, three (8%) were Black or African American, and one (3%) was Asian. In phase 1, no dose-limiting toxicity event occurred. The recommended phase 2 dose of ramucirumab was 10 mg/kg. Median follow-up for patients on phase 2 was 14·8 months (IQR 4·9–31·0). In phase 2, 18 (55%; 95% CI 38–70) of 33 evaluable patients had an objective response, including confirmed complete response in 11 patients, confirmed partial response in six patients, and unconfirmed partial response in one patient. The most common grade 3 or worse adverse events were dysphagia (14 [38%] of 37 patients), lung infection (11 [30%]), lymphocyte count decrease (ten [27%]), hypophosphataemia (nine [24%]), and hypertension (eight [22%]). No treatment-related deaths were recorded. Interpretation Ramucirumab and pembrolizumab were safe to administer to patients with recurrent or metastatic HNSCC, and the objective response rate with this combination as first-line treatment for recurrent or metastatic HNSCC was favourable. Further studies of ramucirumab and pembrolizumab in patients with recurrent or metastatic HNSCC are warranted. Funding Lilly and the Joseph Sanchez Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
活力的钢笔完成签到,获得积分10
1秒前
1秒前
我爱科研完成签到,获得积分10
2秒前
共享精神的应助被weddcf采纳,获得10
2秒前
蔓越莓发布了新的文献求助10
2秒前
cloudss发布了新的文献求助10
3秒前
3秒前
sevenseven完成签到,获得积分10
3秒前
3秒前
zhouzhou完成签到 ,获得积分10
3秒前
甜美冰旋完成签到,获得积分10
3秒前
斯文败类的应助被FeCl采纳,获得10
4秒前
nannan完成签到,获得积分10
4秒前
现代的东蒽完成签到,获得积分10
4秒前
脑洞疼的应助被Duxize采纳,获得10
4秒前
爆米花的应助被1820采纳,获得10
5秒前
start发布了新的文献求助10
5秒前
人生如梦完成签到,获得积分10
5秒前
海猫食堂完成签到,获得积分10
6秒前
4XXXX完成签到,获得积分10
6秒前
6秒前
7秒前
7秒前
微笑发布了新的文献求助10
7秒前
AnZeng完成签到,获得积分10
7秒前
天天快乐的应助被xdlongchem采纳,获得10
7秒前
亳亳发布了新的文献求助10
7秒前
shayu发布了新的文献求助10
7秒前
Dentist_Gao完成签到 ,获得积分10
8秒前
mmooo完成签到 ,获得积分10
8秒前
秀秀完成签到,获得积分10
8秒前
9秒前
蜡小新完成签到,获得积分10
9秒前
姜渡完成签到 ,获得积分10
9秒前
水煮电吹风的应助被浅夏初雨采纳,获得10
9秒前
drccy的应助被xyx277采纳,获得10
9秒前
无花果的应助被微笑采纳,获得10
10秒前
斯文败类的应助被sl采纳,获得10
10秒前
XM给XM的求助进行了留言
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180617
求助须知:如何正确求助?哪些是违规求助? 9570702
关于积分的说明 21813868
捐赠科研通 7776860
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557571
邀请新用户注册赠送积分活动 2479253